Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 1/2 1

Status

Completed 19Unknown 6Terminated 6Recruiting 6Withdrawn 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Conditions

Breast Neoplasms 1871Neoplasms 1257Colorectal Neoplasms 1057Carcinoma, Non-Small-Cell Lung 1012Stomach Neoplasms 802Carcinoma, Hepatocellular 785Lung Neoplasms 769Prostatic Neoplasms 697Pancreatic Neoplasms 577Rectal Neoplasms 449Ovarian Neoplasms 406Colonic Neoplasms 405Neoplasm Metastasis 403Uterine Cervical Neoplasms 400Recurrence 382Leukemia, Myeloid, Acute 372Esophageal Neoplasms 363Multiple Myeloma 339Lymphoma 335Head and Neck Neoplasms 330Melanoma 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 292Brain Neoplasms 264Urinary Bladder Neoplasms 256Liver Neoplasms 225Nasopharyngeal Carcinoma 223Leukemia 218Lymphoma, Large B-Cell, Diffuse 216Polycystic Ovary Syndrome 210Squamous Cell Carcinoma of Head and Neck 205

Interventions

Everolimus 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Unknown × Advanced Malignancies × Clear all
NCT04671875 2024-03-13

A Clinical Study of MIL93 in Solid Tumors.

Beijing Mabworks Biotech Co., Ltd.

Phase 1 Unknown
228 enrolled

Advanced Malignancies

NCT04916119 2022-09-16

Study of IBI323 in Patients With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Unknown
322 enrolled

Advanced Malignancies

NCT04085185 2022-09-14

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Unknown
268 enrolled

Advanced Malignancies

NCT05024305 2022-03-09

Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.

Shandong TheraWisdom Biopharma Co., Ltd.

Phase 1 Unknown
81 enrolled

Advanced Malignancies

NCT04340427 2020-07-01

A Study of TQB3455 Tablets in Subjects With Advanced Malignancies

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown
50 enrolled

Advanced Malignancies

NCT01079702 2010-03-03

m-TOR

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Unknown
35 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡